Oyster Point Pharma to Release Third Quarter 2021 Financial Results
PRINCETON, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) – Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of leading pharmaceutical therapies to treat ocular surface diseases, today announced that it will release its third quarter 2021 financial results on Thursday, November 4, 2021, after market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. EST.
Conference call details
To access the live call by phone, please dial (855) 548-1220 (US / Canada) or (602) 563-8619 (International). The conference call ID is 4538958. A telephone replay will be available for approximately 7 days after the live conference call. To access the telephone replay, please dial (855) 859-2056 (US / Canada) or (404) 537-3406 (International). The conference ID number is 4538958.
The webcast will be available on the company’s website at www.oysterpointrx.com in the âEvents and Presentationsâ section.
About Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of leading pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYA â¢ nasal spray (varenicline solution) for the treatment of signs and symptoms of dry eye. Oyster Point has a growing portfolio of clinical and preclinical programs and continues to expand its research and development portfolio through internal innovation and external collaborations. Oyster Point continually strives to advance cutting-edge science and provide therapies to address the unmet needs of patients with ophthalmic disease and the eye care professionals who care for them. For more information, visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn.
About dry eye and the role of tear film
Dry eye is a chronic disease that affects approximately 38 million people in the United States and is increasing in prevalence. It can cause persistent stinging, scratching, burning sensations, sensitivity to light, blurred vision, and eye strain. Dry eye is a multifactorial disease of the ocular surface characterized by rupture of the tear film. The human tear film is a complex mixture of over 1,500 different proteins, including growth factors and antibodies, as well as many classes of lipids and mucins. The natural tear film protects and lubricates the eyes, removes foreign particles, contains growth factors and antimicrobial components, and creates a smooth surface that forms the main refractive surface of the eye.
LifeSci Advisors, LLC
Sheryl Seapy, the real chemistry